Human papillomavirus-related genital disease in the immunocompromised host: Part II
- PMID: 22583721
- DOI: 10.1016/j.jaad.2010.12.049
Human papillomavirus-related genital disease in the immunocompromised host: Part II
Abstract
Human papillomavirus is responsible for common condyloma acuminata and a number of premalignant and malignant anogenital lesions. The immunocompromised population is at particular risk because of a higher incidence of malignant transformation. Lesions in this population may prove refractory to standard treatment. This is part II of a two-part review that will discuss the treatment of condyloma acuminata and vaginal, vulvar, penile, and anal intraepithelial neoplasias. This article will provide an updated review of available treatments, with a focus on recent advances and the challenges faced in successfully treating human papillomavirus lesions in the immunocompromised host.
Copyright © 2011 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.
Comment in
-
Should intralesional bleomycin be used in the treatment of human papillomavirus-related genital disease in the immunocompromised host?J Am Acad Dermatol. 2013 Apr;68(4):680-681. doi: 10.1016/j.jaad.2012.08.047. J Am Acad Dermatol. 2013. PMID: 23522412 No abstract available.
-
Response to "Should intralesional bleomycin be used in the treatment of HPV-related genital disease in the immunocompromised host?".J Am Acad Dermatol. 2013 Apr;68(4):681-682. doi: 10.1016/j.jaad.2012.10.030. J Am Acad Dermatol. 2013. PMID: 23522413 No abstract available.
Similar articles
-
Human papillomavirus-related genital disease in the immunocompromised host: Part I.J Am Acad Dermatol. 2012 Jun;66(6):867.e1-14; quiz 881-2. doi: 10.1016/j.jaad.2010.12.050. J Am Acad Dermatol. 2012. PMID: 22583720 Review.
-
The management of condyloma acuminata in the pediatric population.Pediatr Ann. 2009 Jul;38(7):368-72. doi: 10.3928/00904481-20090622-05. Pediatr Ann. 2009. PMID: 19685656 Review. No abstract available.
-
Should intralesional bleomycin be used in the treatment of human papillomavirus-related genital disease in the immunocompromised host?J Am Acad Dermatol. 2013 Apr;68(4):680-681. doi: 10.1016/j.jaad.2012.08.047. J Am Acad Dermatol. 2013. PMID: 23522412 No abstract available.
-
Response to "Should intralesional bleomycin be used in the treatment of HPV-related genital disease in the immunocompromised host?".J Am Acad Dermatol. 2013 Apr;68(4):681-682. doi: 10.1016/j.jaad.2012.10.030. J Am Acad Dermatol. 2013. PMID: 23522413 No abstract available.
-
Vulvar and vaginal HPV disease.Obstet Gynecol Clin North Am. 2013 Jun;40(2):359-76. doi: 10.1016/j.ogc.2013.03.003. Obstet Gynecol Clin North Am. 2013. PMID: 23732036
Cited by
-
Complete clearance of periungual warts in an immunocompromised patient using diluted intralesional bleomycin.Dermatol Reports. 2022 Nov 30;14(4):9490. doi: 10.4081/dr.2022.9490. eCollection 2022 Nov 21. Dermatol Reports. 2022. PMID: 36545271 Free PMC article.
-
Prevalence of Human Papillomavirus Genotypes in Tehran, Iran.J Res Health Sci. 2022 Oct 19;22(3):e00553. doi: 10.34172/jrhs.2022.88. J Res Health Sci. 2022. PMID: 36511371 Free PMC article.
-
Penile warts: an update on their evaluation and management.Drugs Context. 2018 Dec 19;7:212563. doi: 10.7573/dic.212563. eCollection 2018. Drugs Context. 2018. PMID: 30622585 Free PMC article. Review.
-
[Genital warts in HIV-infected individuals].Hautarzt. 2017 Mar;68(3):192-198. doi: 10.1007/s00105-017-3938-z. Hautarzt. 2017. PMID: 28160045 Review. German.
-
Multiple Oral Mucosal Hamartomas in a 34-Year Old Female.Head Neck Pathol. 2017 Sep;11(3):393-398. doi: 10.1007/s12105-016-0777-7. Epub 2017 Jan 10. Head Neck Pathol. 2017. PMID: 28074344 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
